US44842L1035 - ADR
HUTCHMED CHINA-ADR
NASDAQ:HCM (4/23/2024, 4:20:01 PM)
After market: 18.25 0 (0%)18.25
+1.31 (+7.73%)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 2,025 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
HUTCHMED CHINA-ADR
48th Floor, Cheung Kong Center, 2 Queen's Road Central
Hong Kong
P: 85221281188
CEO: Christian Hogg
Employees: 2025
Website: https://www.hutch-med.com/
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory...
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in...
Here you can normally see the latest stock twits on HCM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: